Search
|
Browse by Day
|
Author Index
Author Index: I
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Icten, Z. G.
WHEN SHOULD END-STAGE LIVER DISEASE (ESLD) PATIENTS UPDATE THEIR MODEL FOR END-STAGE LIVER DISEASE (MELD) SCORE?
Ieraci, L.
THE COST-EFFECTIVENESS ANALYSIS OF FIVE NON-INVASIVE CARDIAC IMAGING TECHNOLOGIES IN ONTARIO
PHARMCOGENETIC TESTING AND EVIDENCE-BASED DECISION-MAKING IN ONTARIO: THE APPLICATION OF ONTARIO'S DECISION DETERMINANTS FRAMEWORK TO THE EVALUATION OF PHARMACOGENETIC TESTS
THE DIAGNOSTIC ACCURACY AND COST-EFFECTIVENESS OF SEROLOGIC TESTS IN THE DIAGNOSIS OF CELIAC DISEASE
IJzerman, M. J.
EFFICIENCY FRONTIER ANALYSIS USING THE ANALYTIC HIERARCHY PROCESS
USING AHP WEIGHTS TO FILL MISSING GAPS IN MARKOV DECISION MODELS
Imperiale, T. F.
SECOND-LOOK ENDOSCOPY FOR BLEEDING PEPTIC ULCER DISEASE: A DECISION- AND COST-EFFECTIVENESS ANALYSIS
IMPACT OF QUANTITATIVE INFORMATION AND A NUDGE ON ATTITUDES TOWARD COLORECTAL CANCER SCREENING
Imrie, K.
COST-EFFECTIVENESS IN CANADA OF RITUXIMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Ingham, M.
OBSERVED VERSUS RECOMMENDED PATIENT PRESCRIPTION REFILL BEHAVIOUR - ASSESSMENT OF ADALIMUMAB AND ETANERCEPT PRESCRIPTION GAPS FOR THE FIRST YEAR OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
Inman, B.
MEASURING THE BENEFIT OF PSA SCREENING FROM THE PATIENT AND SOCIETAL PERSPECTIVES
Inoue, H.
COST-EFFECTIVE TREATMENT THRESHOLDS FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN
Inoue, Y.
THE IMPACT OF TUMOR KINETIC GROWTH MODELS ON THE COST-EFFECTIVENESS OF PERIODIC SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
Ishida, H.
THE IMPACT OF TUMOR KINETIC GROWTH MODELS ON THE COST-EFFECTIVENESS OF PERIODIC SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA
Isogai, P. K.
COMPARISON OF THREE INDIRECT MEASURES OF HEALTH UTILITIES IN HIV
MODEL TO PREDICT HEALTH UTILITY SCORES FROM CD4 COUNT IN HIV
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
